Kyntra Bio

Kyntra Bio OCF Margin

The Operating Cash Flow Margin of Kyntra Bio (KYNB) as of Oct 20, 2026 is -74.13 %. In the previous year, Operating Cash Flow Margin was -465.88 % — a change of -84.09% (higher).

OCF Margin

-74.13 %

YoY

-84.09%

Last updated:

Operating Cash Flow Margin of Kyntra Bio is 2025 -74.13 % . Operating Cash Flow Margin of Kyntra Bio was 2024 -465.88 % . It decreases by -84.09% higher compared to the previous year.

The Kyntra Bio OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-35.76 USD
Jan 1, 2019
-30.68 USD
Jan 1, 2020
46.28 USD
Jan 1, 2021
-34.95 USD
Jan 1, 2022
-103.69 USD
Jan 1, 2023
-673.08 USD
Jan 1, 2024
-465.88 USD
Jan 1, 2025
-74.13 USD
The Kyntra Bio OCF Margin history
YEAROCF MarginYoY
-74.13 %-84.09%
-465.88 %-30.78%
-673.08 %+549.10%
-103.69 %+196.72%
-34.95 %-175.51%
46.28 %-250.87%
-30.68 %-14.21%
-35.76 %-32.44%
-52.93 %-1,437.17%
3.96 %-138.54%
-10.27 %-163.05%
16.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kyntra Bio Stock analysis

What does Kyntra Bio do? Kyntra Bio Inc is a biopharmaceutical company based in San Francisco, United States, operating within the health care sector. Listed on November 14, 2014, the firm engages in the discovery, development, and commercialization of novel therapeutics. It leverages expertise in hypoxia-inducible factor and connective tissue growth factor biology to create innovative medicines. The company is developing roxadustat for anemia associated with chronic kidney disease, myelodysplastic syndromes, and chemotherapy-induced anemia. Additionally, it is researching pamrevlumab for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. The organization currently employs 34 people in its operations. Kyntra Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kyntra Bio stock

Operating Cash Flow Margin of Kyntra Bio is -74.13 % in 2025.

Operating Cash Flow Margin of Kyntra Bio changed from -465.88 % to -74.13 %, representing a -84.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Kyntra Bio since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Kyntra Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Kyntra Bio

All Key Metrics — Kyntra Bio